Novartis agrees to acquire Avidity Biosciences, an
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases Advances the Novartis xRNA strategy by adding a scientifically robust, muscle-directed, Antibody Oligonucleotide Conjugates (AOCs™) platform and first-in-disease pipeline Expected to unlock multi-billion-dollar opportunities with planned product launches before 2030 Raises expected … Read more